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Abstract
Nerve Growth Factor, a neurotrophin, may have other functions, including a role in depressive
disorders. The present study sought to determine whether NGF would (1) have antidepressant-like
effects and (2) behave similarly to or differently from other well-recognized antidepressants. Over
a broad dose-range, NGF reduced the exaggerated swim test immobility exhibited by the Flinders
Sensitive Line (FSL) rats, but at a standard dose of 40 ng/ml, it was not as effective as
desipramine (DMI, 5 mg/kg). The low social interaction behavior and locomotor activity of the
FSL rats were less affected by NGF than was the immobility. Acute treatment with NGF did not
induce c-fos expression in brain regions known to be activated by other acute antidepressants. The
fact that chronic treatment with DMI blunted the corticosterone response to fluoxetine was
replicated in this study. However, chronic treatment with NGF did not alter this response.
Similarly, chronic treatment with fluoxetine blunted 5-HT1A and 5-HT2A receptor-mediated
responses, whereas chronic treatment with NGF was without effect. Thus, NGF has
antidepressant-like effects but does not appear to have biochemical actions typical of other
antidepressants.
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Neurotrophins, including nerve growth factor (NGF) and brain-derived nerve growth factor
(BDNF), are recognized to play roles other than their classical trophic effects (Altar, 1999;
Duman, 2002). One such function that has become increasingly investigated is a role in
depressive-like behavior. Work has been particularly active with regard to BDNF, with
demonstrations that it is elevated in rats undergoing antidepressant treatments (Chen et al.,
2001), that it may have antidepressant-like effects after central injections (Shirayama et al.,
2000; Siuciak et al., 1997), and that depressed individuals have a deficiency of BDNF
(Karege et al., 2002; Shimizu et al., 2003). Much less attention has been devoted to the
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potential involvement of NGF in depressive-like behavior and antidepressant action,
although there are some supporting data. A key finding is that although both NGF and
BDNF are reduced in certain brain regions of the Flinders Sensitive Line (FSL) rat, a genetic
animal model of depression (Angelucci et al., 2000; Overstreet et al., 2005), the application
of electroconvulsive shock, a robust antidepressant treatment in rats, elevated NGF only
(Angelucci et al., 2003). Anecdotal experience with dogs suffering from separation anxiety
and treated with a formulation of low concentration NGF indicated that they exhibited
improved behavior as a consequence of therapy (unpublished observations, 2002).
Therefore, there was an interest in systematically evaluating the antidepressant potential of
NGF in preclinical animal models.
The FSL rat is innately more immobile in the forced swim test than its control counterpart,
the Flinders Resistant Line (FRL) rat, and exhibits a decrease in immobility following
chronic, but not acute, treatment with desipramine (DMI) or sertraline (Pucilowski and
Overstreet, 1993). The FSL rat exhibits other features that are similar to those found in
human depressives, such as increased REM sleep (Benca et al., 1996; Shiromani et al.,
1988), has serotonergic abnormalities that are corrected following chronic antidepressant
treatments (Zangen et al., 1997), and responds to other antidepressants that appear to be
clinically useful (See Overstreet, 2002; Overstreet et al., 2005).
It is important to know not only whether NGF will have antidepressant-like effects but also
whether the mechanisms underlying these effects are similar to or different from those of the
classical antidepressants. Consequently, three paradigms were examined in FSL or normal
outbred rats: 1) regional brain c-fos expression after injection of NGF and/or exposure to the
swim test (Duncan et al., 1996); 2) induction of corticosterone elevation by acute fluoxetine
in rats chronically treated with NGF or DMI (Duncan et al., 1998); 3) induction of
hypothermia or head shakes by serotonin agonists in rats chronically treated with NGF or
fluoxetine (Albert et al., 1996; Gray and Roth, 2001; Stahl, 1994; Toth, 1996).
Methods
1. Antidepressant Experiments
In preliminary studies, NGF was compared with vehicle or other ingredients in a medicine;
NGF significantly reduced immobility while none of the other ingredients had a significant
effect (unpublished findings, 2001). These encouraging findings led to the dose-response
study described here.
Animals—The FSL and FRL rats were selected from breeding colonies maintained at the
University of North Carolina Bowles Center for Alcohol Studies. They were housed in
groups of three in temperature- and humidity-controlled rooms under a 12:12 light:dark
cycle (lights on 0700-1900). Rats were randomly divided into nine FSL groups and one FRL
reference group and then given the treatments described below.
Research Design—The basic design included the following treatment groups: FRL rats
given vehicle; FSL rats given vehicle; FSL rats given DMI as a positive control; and FSL
rats given various doses of NGF. The concentration of NGF was altered in the solution so
that every rat received an injection of 0.2 ml/kg, regardless of weight. The concentrations of
the NGF solutions were 2.96, 14.8, 64, 320 pg/ml and 1.6, 8, 40 (standard dose) and 80 ng/
ml). The weights of the rats did not differ by more than 20 grams, so the doses did not differ.
Chronic Treatment of NGF—FSL Rats (n=8 or more) were divided into 9 treatment
groups (vehicle and 8 different doses of NGF). Rats were injected s.c. with 0.2 ml of the
allocated dose for 14 consecutive days. Approximately 20 hr after the last treatment the rats
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were placed in the social interaction arena for a 5-min session. Approximately 90 min later,
they were placed individually in the swim tank for a 5-min recording of swimming behavior.
A saline-treated Flinders Resistant Line (FRL) group (n=8), which swims significantly more
than the FSL rats, was tested in the two behavioral tasks as a reference group. A positive
control FSL group was used also; DMI (5 mg/kg) was injected for 14 consecutive days and
the behavioral tests were conducted between 21 and 23 hours after the last injection.
In a separate study, 24 FSL rats were used to attempt a replication of the findings with NGF.
The three treatment groups were vehicle, 40 ng NGF and 5 mg/kg desipramine. After 14
days of daily treatments, the rats were tested in the social interaction and forced swim tests.
Behavioral Tests—Approximately 20 hr after the last treatment, rats with similar body
weights were placed in a square test arena (60 × 60 cm, with 16 15 × 15 cm squares marked
on the floor) for the testing of social interaction. The amount of time spent in social
interaction (grooming, licking, sniffing, crawling over or under) was recorded during a 5-
min session by an experienced observed who was blind to the treatment condition. This
measure provides one index of anxiety-like behavior, with more “anxious” rats spending less
time in social interaction (File and Seth, 2003; Overstreet et al., 2003). In addition, a motor
activity measure was collected. The total number of lines crossed during the session
provided a measure of general activity.
The swim tank was 18 cm in diameter and 40 cm tall. The tank was filled with enough 25°C
water so the rat could not touch bottom with its feet. The rat was placed in the swim tank for
a single 5-min session 21-23 hr after the last treatment and the seconds of immobility was
scored by an observer blind to the treatment condition and rat strain being tested (Overstreet,
1993; Zangen et al. 1997).
Statistical Analyses—The data for the three measures in the chronic treatment study
were summarized into means±s.e.m. for each of the 10 treatment groups. For the swim test
the immobility scores were converted to swimming scores to make it consistent with the
other behavioral measures, where the score for the FSL rat is lower than the score for the
FRL rat. Graphical representations of the findings were compiled using Prism software.
Initially, the data for each measure were subjected to one-way ANOVAs. If the ANOVA
revealed significant group differences, follow-up Tukey's tests were carried out to elucidate
the pattern of group differences. The GBstat software package was used for the statistical
analyses.
2. C-fos Expression
The research design evaluated the acute and chronic effects of NGF (standard dose of 40 ng/
ml) on the regional brain expression of c-fos, an early/immediate gene product that is
associated with increased activity in the brain (e.g., de Medeiros et al., 2005; Duncan et al.,
1996; Morinobu et al, 1995; 1997). Rats were either injected acutely with the standard dose
of NGF (n=4) or vehicle (n=4) or chronically for 14 consecutive days with the same doses of
NGF (n=8) or vehicle (n=8). The rats were briefly handled on two occasions prior to the
start of the injections to minimize the effects of injection stress. The rats were sacrificed two
hours after the acute injections, intracardially perfused with 4% paraformaldehyde and the
brain removed and stored until processed for c-fos expression (Duncan et al., 1996). In the
chronic treatment groups, the rats were exposed to the swim tank between 22 and 24 hr after
the last injection and then sacrificed 2 hr later and the same procedures as for the acutely
treated rats were followed.
C-fos expression was assessed by immunochemistry, following the methods developed by
Duncan et al., (1996). For all conditions, rats were anesthetized with 70 mg/kg of
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pentobarbital sodium two hr. after initiation of the different procedures and perfused
transcardially at a rate of 35-40 ml/min with ice-cold 100 mM sodium phosphate-buffered
saline for 4 min (PBS, pH = 7.4), followed by 4% paraformaldehyde in phosphate buffer
(PB) for 7 min. Brains were post-fixed overnight in 4% paraformaldehyde in PB. Numerous
studies have shown that a 2 h delay following presentation of a variety of stimului is optimal
for immunocytochemical analysis of Fos in brain (Malberg et al., 2000; for review see
[Slattery et al., 2005]). Vibratome sections of brain (60 micrometers) were cut and placed in
PBS contained in 24-well tissue culture dishes. Sections were treated with 10% normal
rabbit serum and 0.2 % Triton X-100 in PBS for 30 min and then were then incubated for
48-72 h at 4 °C with a polyclonal Fos antiserum raised in rabbits (1:20000 dilution;
Biognesis, Brentwood, NH). The antibody was raised against a synthetic peptide
corresponding to conserved regions of mouse and human Fos. The antibody generated
exclusively nuclear specific staining. Since it is uncertain whether the antibody recognizes
Fos-related antigens as well as Fos, results are described as Fos-like immunoreactivity (Fos-
LI). However, in previous work, staining with the antisera was maximal at 2 hr, was reduced
substantially by 4 h, and was not different from controls by 6 h (Malberg et al., 2000). Thus,
since the induction of Fos-related antigens is delayed relative to Fos and persists well
beyond 6h after a stimulus (Slattery et al., 2005), the time course of staining with the
antibody is consistent with a recognition of only Fos. After incubation with the Fos
antiserum, sections were processed through 3 rinses of PBS and incubated for 1 h with
biotinylated rabbit-antigoat antibody (Vector Laboratories, Burlingame, CA). After 3 rinses
with PBS the sections were incubated with avidinbiotin complex (Vector Laboratories) for 1
h. With an additional 3 rinses with PBS, sections were placed in a solution containing 0.05%
3,3′-diaminobenzidene tetrahydrochloride (DAB), 0.005% cobalt chloride, 0.007% nickel
ammonium sulfate, and 0.003% hydrogen peroxide. For each animal, anatomically intact/
high quality regions from both left and right sides of the brain where possible were isolated
and all Fos-LI-positive cells within a defined area (Table 2) were counted. Mean cell counts
for each animal/region were used to calculate differences across groups.
Cells exhibiting Fos-LI in select brain regions were counted in a circular field defined by the
area of section viewed with a 10 × or 20 × objective, depending of the size of region of
interest. In other brain regions, the number of cells within defined histological regions were
counted. This approach of cell counting was designed to accurately reflect the number of
cells within specific brain regions.
Statistical Analyses—The data for c-fos expression were analyzed separately for each
brain region. Initially, the acute and chronic studies were treated as independent and t tests
were used to compare the vehicle- and NGF-treated groups. However, because the acute
groups were not exposed to the swim test and the chronic groups were, the effects of
exposure to the swim tank could also be evaluated. Therefore, a global 2-way ANOVA was
carried out, with swim test exposure and NGF treatment as the two independent variables.
3. Blunted Corticosterone Response as Antidepressant Effect
Fluoxetine acutely stimulates blood corticosterone levels (Duncan et al., 1998). However,
the effects of fluoxetine are reduced in rats chronically treated with antidepressants,
including DMI (Duncan et al., 1998). Consequently, the response to fluoxetine was
determined in rats chronically treated with NGF and compared with rats chronically treated
with DMI.
Animals—Outbred Sprague-Dawley rats were used for this study because most of the
previous studies used this strain (e.g., Duncan et al., 1998). Thirty rats were purchased from
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Charles-River (Raleigh, NC) at about 70 days of age. They were divided into three equal
groups of 10 (vehicle treatment, NGF treatment, DMI treatment).
Procedure—Rats were treated for 21 consecutive days with either vehicle (4 ml/kg), 4 ng
NGF (0.2 ml/rat), or 15 mg/kg DMI (4 ml/kg). Approximately 22 hr after the 18th injection,
the rats were placed in cylinders filled with 25 °C water and immobility was recorded by an
observer blind to treatment during a single 5-min session. After the test, the rats were dried
thoroughly and returned to their home cages. The daily scheduled treatment was given about
90 min later. At 22-24 hr after the last treatment (21st), the rats were injected i.p. with 5 mg/
kg fluoxetine. Forty min later the rats were sacrificed by decapitation, blood collected and
plasma samples stored at −80 °C until assays of corticosterone could be carried out, using a
radioimmunoassay kit (Sigma).
Statistical Analysis—Data were analyzed initially by one-way ANOVAs. When these
revealed significant differences, Tukey's protected t tests were carried out to determine the
pattern of group differences.
4. Blunted 5-HT1A and 5-HT2A Responses as Antidepressant Effect
A functional down-regulation of 5-HT1A and 5-HT2A receptor responses has been
commonly observed in rats treated chronically with antidepressants, particularly selective
serotonin reuptake inhibitors (Stahl, 1994; Toth, 1996). Because these responses may or may
not be accompanied by parallel decreases in the respective receptors (Albert et al., 1996;
Gray and Roth 2001), we decided to use functional assays in this study. Specifically,
hypothermia was used to assess 5-HT1A receptor function (Overstreet et al., 1994) and
headshakes were used to assess 5-HT2A receptor function. It was predicted that these
responses would be blunted after chronic treatment with fluoxetine (e.g. Albert et al, 1996;
Gray and Roth, 2001) and that they would also be blunted after NGF treatment if NGF were
acting like fluoxetine.
Animals—Outbred Sprague-Dawley rats were used because these rats were the primary
group used in previous studies of 5-HT1A and 5-HT2A receptor function. Two groups of 30
rats were obtained, one batch to study 5-HT1A receptor function and one batch to study 5-
HT2A receptor function.
Procedure—Rats were chronically treated for 21 consecutive days with either vehicle, 5
mg/kg fluoxetine (1 ml/kg) or 4 ng NGF (0.2 ml/rat). At about 22 hr after the 18th injection
the rats were challenged with 0.25 mg/kg 8-OH-DPAT, a 5-HT1A receptor agonist, or 5 mg/
kg DOI, a 5-HT2A/C receptor agonist. Temperature was recorded 45 min after the 8-OH-
DPAT injection and related to previously recorded baselines. Headshakes were scored in the
DOI-treated rats continuously between 15 and 45 min after the injections. The rat's normal
scheduled treatment was given about one hour after the challenge treatments. Chronic
treatment continued for two more days and then the swim test was conducted about 22 hr
after the last (21st) injection.
Statistical Analysis—Data were analyzed initially by one-way ANOVAs. When these
revealed significant differences, Tukey's protected t tests were carried out to determine the
pattern of group differences.
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1. Chronic NGF Treatment
The results are summarized in Figures 1 & 2 (Swimming), 3 & 4 (Social Interaction) and 5
& 6 (Line Crossings). For each variable, the first figure of the pair compares the standard
dose of NGF with FRL rats and FSL rats treated with vehicle or DMI, a positive control.
The second figure of the pair illustrates the findings from all of the NGF treatments. Thus,
Figure 1 shows that while NGF increases swimming significantly in the FSL rats, the effect
is not as robust as that for DMI because FSL rats treated with DMI are not significantly
different from the FRL rats. In other words, DMI at a dose of 5 mg/kg/day for 14 days
completely normalized the behavior of the FSL rats, but NGF did not. Figure 2 shows that,
as reported in Figure 1, FSL rats treated with vehicle and the standard dose of NGF (40 ng/
ml) were significantly different from the FRL rats (although they are also different from
each other). Overall, there was a significant treatment effect (F[9,83] = 6.66, p < 0.001).
Like 40 ng/ml, the doses of 2.96 and 14.8 pg/ml failed to normalize fully the behavior of the
FSL rats. However, the other five treatments induced swimming scores in the FSL rats that
were not significantly different from the scores of the FRL rats.
The results in Figure 1 are consistent with the findings above that the standard dose of NGF
has only a partial counteracting effect on the exaggerated swim test immobility. However,
for social interaction, NGF did not have a significant effect at all on the abnormally low
social interaction in the FSL rats. In contrast, chronic treatment with DMI increased social
interaction behavior in the FSL rats to the level of the FRL rats (Fig. 3). Thus, DMI
normalized both behaviors in the FSL rats, whereas the standard dose of NGF only partially
normalized the abnormal swimming behavior. As shown in Figure 4, all of the NGF
treatments slightly increased social interaction behavior above that seen in the vehicle-
treated FSL rats. However, no single treatment produced social interaction behavior similar
to that observed in the FRL rats (Fig. 4). Indeed, the one-way ANOVA indicated that there
were no significant differences (F[9,83] = 1.25, NS).
The results for locomotor activity, illustrated in Figures 5 & 6, present a different pattern
than for swimming and social interaction. Here the standard dose of NGF increased activity
of the FSL rats, whereas DMI did not. Still, the activity of the FRL rats was even higher
(Fig. 5). As shown in Figure 6, there were significant differences among the various
treatments (F[9,83] = 6.70, p < 0.001). The two lowest doses of NGF also increased activity,
but the other ones did not.
The fact the NGF did increase activity under some conditions could suggestion that the
effects on swimming are merely secondary to the effects on activity. To investigate this
further, Analyses of Covariance were carried out on immobility and activity. When activity
scores were controlled in the initial study, there was no significant effect on swimming.
(F[3,32] = 0.95, NS) However, when activity scores were controlled in the second study, a
highly significant effect of treatment on immobility remained (F[9,129] 17.37, p < 0.001).
Thus, swim test immobility is not simply dependent upon locomotor activity.
The results of the replication study, reported in Table 1, supported the above conclusion.
There were no significant differences for social interaction (F[2,20] = 0.21, NS) or line
crosses (F[2,20] = 0.50, NS), but the differences in immobility were highly significant
(F[2,20] = 47.7, p < 0.0001) Furthermore, an analysis of covariance using locomotor activity
as the covariate still revealed a highly significant effect on immobility (F[2,20] = 49.04, p <
0.0001).
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The results are summarized in Table 2. A wide range of brain regions was sampled and two-
way ANOVAs were used to analyze the data in each region. Despite the number of brain
regions sampled, there were no significant effects of either acute or chronic NGF treatment
(all F, NS). Even in the four brain regions (Table 2) where there was a significant effect of
swim test exposure (PVN, F[1,16] = 70.47; Central Amygdala, F[1,16] = 11.14; Medial
Amygdala, F[1,16] =11.72; and shell of the Nucleus Accumbens, F[1,16] = 10.63), NGF
treatment did not modify the effects of the swim test. Thus, NGF does not appear to induce
brain c-fos expression, nor does it modify expression induced by swim test exposure.
3. Blunted Corticosterone Response after Chronic Antidepressant Treatment
The results are summarized in Figure 7. In the top panel of the figure are the scores for swim
test immobility. The vehicle-treated rats are significantly more immobile than either the
NGF- or DMI-treated rats (F[3,28] = 15.18, p < 0.001). Both NGF and DMI had
antidepressant-like effects. In contrast, as shown in the bottom panel of Figure 7, only
chronic DMI treatment induced a blunting of the corticosterone response to fluoxetine. NGF
was without effect. A one-way ANOVA confirmed the group differences (F[3,26] = 3.84, p
< 0.05) and Tukey's protected t tests established that the DMI-treated group was
significantly different from the other three groups.
4. Blunted 5-HT1A and 5-HT2A Responses after Chronic Treatment
The results are summarized in Table 3. In the first column are shown the data for swim test
immobility. There were significant group differences (F[2,26] = 40.24, p < 0.0001) and both
fluoxetine and NGF significantly reduced immobility. However, both the number of head
shakes after DOI, a 5-HT2A/C agonist, and the degree of hypothermia after 8-OH-DPAT, a
5-HT1A agonist, were reduced only in the fluoxetine-treated rats. Tukey's tests confirmed
that the fluoxetine-treated rats were significantly different from the other two groups. Thus,
chronic treatment with NGF produces a similar antidepressant-like response as does
fluoxetine, but it does not induce blunting of serotonergic responses.
Discussion
The present findings may be the first to report that injected NGF has an antidepressant-like
effect; a preliminary report of these findings has been presented (Overstreet et al., 2004a).
The reduction in immobility after chronic NGF treatment was seen under a variety of
conditions. Several different doses of NGF reduced the exaggerated immobility (increased
swimming) of the FSL rat and they tended not to counteract the low social interaction
behavior and had mixed effects on the reduced locomotor activity. Furthermore, chronic
treatment with NGF reduced immobility in outbred Sprague-Dawley rats to an extent similar
to fluoxetine but not as strong as DMI. These findings are consistent with the suggestions of
others that NGF may play a role in depression (Angelucci et al., 2000, 2003). It is quite
remarkable that these antidepressant effects can be observed with such low doses. The
standard concentration of NGF, which was used for most of these studies, was 40 ng/ml.
With the rats in these studies weighing an average of 400 grams, a dose of 100 ng/kg was
used. Most other antidepressant compounds require higher doses; for example, DMI and
fluoxetine are typically administered in a dose of 5 mg/kg (Overstreet et al., 2005) and
others may require 10 mg/kg or more (Overstreet and Griebel, 2004; Overstreet et al.,
2004b).
The fact that NGF treatment also increases locomotor activity under some conditions raises
the possibility that the reduction in immobility is a simple consequence of the stimulant
effects of NGF. However, that cannot be the case, as there were several instances where
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immobility was reduced without an effect on locomotor activity. Data from other studies
reinforce the view that antidepressant effects on locomotor activity are independent of those
on immobility. In a recent study, for example, both citalopram and DMI reduced swim test
immobility in the FSL rats, but only citalopram increased locomotor activity (Overstreet et
al., 2004b). Earlier on, it was reported that the psychomotor stimulants like amphetamine
and scopolamine do not decrease immobility (Overstreet et al., 1995). A key point about the
present data is that NFG treatment consistently reduced immobility under a variety of
conditions but the effects on locomotor activity are only seen occasionally.
To integrate these results we can describe the profile for DMI and then determine which, if
any, of the NGF treatments resemble this profile. As indicated earlier, DMI increases
swimming to the level of the FRL rats (Fig. 1) and also increases social interaction (Fig. 3),
but does not affect locomotor activity (Fig. 5). 2.96 pg and 14.8 pg of NGF normalize
swimming (Fig. 2); but do not increase social interaction (Fig. 4) or locomotor activity (Fig.
6). Drugs that increase activity are not looked upon favorably as potential antidepressants
because of possible nonspecific stimulant effects. Therefore, the robust effects on swimming
of 8 and 40 ng of NGF are problematic. However, this increase is still below the activity
exhibited by the FRL rats (Fig.6), so it may be a partial normalization. Under this view, 2.96
pg and 8 and 40 ng of NGF would be the best because they tend to normalize each of the
abnormal behavioral responses of the FSL rats.
In an attempt to elucidate the basis of the antidepressant effects of NGF, we examined three
paradigms that have been commonly used to investigate the mechanisms of action of
antidepressants. The first was regional brain c-fos expression. This measure was recorded
both after acute treatment with NGF and after chronic treatment in which the animals were
sacrificed two hours after exposure to the swim tank. Neither of these procedures provided
any evidence that NGF was acting like typical antidepressants. Both Beck (1995) and
Dahmen et al. (1997) reported that a variety of antidepressants increased c-fos expression in
the central amygdala following acute administration. Yet there was no such change after
acute treatment with NGF (Table 2).
The present study included groups that were chronically treated with NGF at a dosage
schedule that reduced swim test immobility. Despite the significant behavioral difference
between the NGF- and vehicle-treated rats, they exhibited similar c-fos expression (Table 2).
In contrast, other antidepressants alter the c-fos response to swim stress following chronic
treatment (Duncan et al., 1996). Thus, NGF appears to be an antidepressant without the
biochemical properties associated with other compounds. Although the rats were handled
prior to the acute injections, there is still the possibility that the effects of injection stress
obscured any effects of NGF itself on c-fos expression. All we can conclude is that the
effects of NGF were not different from the effects of saline vehicle. However, other studies
have concluded that the effects of other antidepressants on c-fos expression do differ from
saline vehicle (Beck, 1995;Dahmen et al., 1997;Duncan et al., 1996).
Another paradigm that has been utilized in an attempt to clarify the mechanism of action of
antidepressants is fluoxetine-induced elevation of corticosterone. Duncan et al. (1998)
demonstrated that the corticosterone response to acute fluoxetine treatment was blunted
following chronic treatment with a variety of antidepressants. The present study confirmed
that chronic treatment with DMI would blunt the corticosterone response to fluoxetine (Fig.
7). However, chronic treatment with NGF had no such effect. At the same time, this study
confirmed the antidepressant-like effects of NGF (Fig. 7). Thus, other antidepressants are
behaving differently from NGF.
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The last paradigm to be considered is the functional down-regulation of 5-HT1A and 5-HT2A
receptors following chronic treatment with antidepressants (Albert et al., 1996; Gray and
Roth, 2001; Overstreet et al., 2005; Stahl, 1994; Toth, 1996). The present report confirmed
previous observations regarding fluoxetine: chronic treatment with this SSRI blunted the
hypothermic response to 8-OH-DPAT, a 5-HT1A receptor agonist, as well as a reduced
behavioral response to DOI, a 5-HT2A/C receptor agonist (Table 3). However, the responses
to these two agonists were unchanged in rats chronically treated with NGF (Table 3), despite
both compounds reducing swim test immobility. Thus, although NGF clearly has
antidepressant-like properties, it does not induce a biochemical profile similar to fluoxetine.
The data presented in this paper allow us to suggest that NGF is a novel antidepressant
because it does not alter c-fos expression in a way similar to other antidepressants or induce
a blunting of the corticosterone response to fluoxetine or a down-regulation of 5-HT1A of 5-
HT2A receptors. What about other mechanisms that might be involved.?
An important consideration is whether NGF is having its antidepressant properties via
actions in the brain or in the periphery. The conventional wisdom is that NGF does not
readily penetrate the blood-brain barrier, so its effects must be related to actions at some
peripheral site. However, there is some evidence that NGF does indeed cross the blood-brain
barrier (Kastin et al., 1999; Poduslo and Curran, 1996), so we cannot determine whether
peripheral or central actions are responsible for it effects. However, it is relevant that
stimulation of the vagus nerve, essentially a peripheral treatment but with central
consequences, has antidepressant-like effects (Nemeroff et al., 2006; Park et al., 2007).
Another consideration is whether the well-known trophic effects of NGF on cholinergic
neurons (e.g., Huy et al., 2008; Williams et al., 1991) could be responsible for its
antidepressant-like effects. The evidence suggests that this mechanism is more likely to
increase immobility, rather than decrease it. Rats with increased cholinergic function tend to
have elevated swim test immobility (Overstreet, 2002; Overstreet et al., 1998). Furthermore,
there is little evidence that cholinergic antagonists have antidepressant-like effects even
though they may increase activity (Overstreet et al., 1995). It is unlikely, therefore, that the
trophic effects of NGF on cholinergic neurons contributes to its antidepressant-like effects.
In conclusion, the antidepressant potential for NGF has been established by demonstrating
that it reduces swim test immobility in both the FSL rat model of depression and in older
outbred Sprague-Dawley rats. However, no effects were seen on c-fos expression, 5-HT1A-
mediated hypothermia, fluoxetine-induced increases in corticosterone, and 5-HT2A-
mediated head shakes. Thus, NGF has actions predictive of antidepressant efficacy with a
novel, as yet undetermined, mechanism of action.
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Figure 1. Swimming in FSL & FRL Rats
The Effects of Chronic Treatment with Desipramine (DMI, 5 mg/kg/day) or NGF (40 ng/kg/
day) on Swim Test Behavior in Flinders Sensitive Line (FSL) Rats. Drugs were injected
daily for 14 days. The 5-min swim test was conducted approximately 23 hr after the last
treatment. The control FRL rats were given vehicle also. The data represent the mean±s.e.m.
Seconds swimming for 8-10 rats.
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Figure 2. Effects of Different Doses of Nerve Growth Factor on Swimming Time in the Forced
Swim Text in FSL Rats
The Effects of Different Doses of Nerve Growth Factor on Swimming in the Forced Swim
Test in FSL rats. Drugs were injected daily for 14 days. The 5-min swim test was conducted
approximately 23 hr after the last treatment. The control FRL rats were given vehicle also.
The data represent the mean±s.e.m. Seconds swimming for 8-10 rats. Groups with the same
letter are not significantly different from each other.
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Figure 3. Social Interaction in FSL & FRL Rats
Social Interaction Behavior in FSL Rats after Chronic Treatment with Desipramine (5 mg/
kg/day) or NGF (40 ng/kg/day). Drugs were injected daily for 14 days. The 5-min social
interaction test was conducted approximately 22 hr after the last treatment. The control FRL
rats were given vehicle also. The data represent the mean±s.e.m. Seconds of social
interaction for 8-10 rats. Groups with different letters are significantly different according to
Tukey's tests.
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Figure 4. Effects of Different Doses of Nerve Growth Factor on Social Interaction Behavior of
FSL Rats
The Effects of Different Doses of NGF on Social Interaction Behavior in FSL Rats. Drugs
were injected daily for 14 days. The 5-min social interaction test was conducted
approximately 22 hr after the last treatment. The control FRL rats were given vehicle also.
The data represent the mean±s.e.m. Seconds of social interaction for 8-10 rats.
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Figure 5. Line Crossings in FSL & FRL Rats
The effects of Chronic Treatment with Desipramine (DMI, 5 mg/kg/day) or NGF (40 ng/kg/
day) on Line Crossings in the Social Interaction Test in FSL Rats. Drugs were injected daily
for 14 days. The 5-min social interaction test was conducted approximately 22 hr after the
last treatment. The control FRL rats were given vehicle also. The data represent the mean
±s.e.m. lines crossed for 8-10 rats. Groups with different letters are significantly different
according to Tukey's tests.
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Figure 6. Effects of Different Doses of Nerve Growth Factor on Locomotor Activity of FSL Rats
The Effects of Different Doses of NGF on Line Crossings in FSL Rats. Drugs were injected
daily for 14 days. The 5-min social interaction test was conducted approximately 22 hr after
the last treatment. The control FRL rats were given vehicle also. The data represent the
mean±s.e.m. lines crossesd for 8-10 rats. Groups with different letters are significantly
different according to Tukey's tests.
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A. DMI is a More Effective Antidepressant than NGF, but Both Reduce Immobility after
Chronic Treatment
B. Only chronic treatment with DMI Reduces Corticosterone Response to Fluoxetine
The Effects of Chronic Treatment with Desipramine (15 mg/kg/day) of NGF (40 or 80 ng/
kg/day) on Corticosterone Response to Fluoxetine. Drugs were given ip chronically for 18
days. Fluoxetine (5 mg/kg) was administered 22 hr after the 18th injection and blood
samples were taken 40 min later for the analysis of corticosterone. The data represent the
mean±s.e.m. μg/ml of corticosterone for 8-10 rats and are presented in the bottom panel.
Treatment continued for a further three days and about 21-23 hr after the last treatment the
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rats were tested in the swim test. The data represent the mean+s.e.m. sec immobile and are
presented in the top panel
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Table 3
Effects of Chronic Treatment with Fluoxetine or NGF on Swim Test Immobility and







Vehicle 221±6a -1.75±0.15a 4.8±1.1a
NGF 162±6b -1.71±0.12a 4.8±1.3a
Fluoxetine 146±7b -0.74±0.06b 1.9±0.6b
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